摘要
目的观察丁酸氢化可的松乳膏联合重组人表皮生长因子凝胶治疗婴幼儿湿疹的疗效及安全性。方法 96例婴幼儿湿疹患者随机分成治疗组(50例)和对照组(46例),治疗组初诊时外用丁酸氢化可的松乳膏联合重组人表皮生长因子凝胶,分别涂于患处,2次/天,错时使用,待皮疹消退后改单用重组人表皮生长因子凝胶继续维持治疗,对照组单独外用丁酸氢化可的松乳膏2次/天,待皮疹消退后改为1次/天,均连用14天。在第7、14天及痊愈后7天记录皮疹情况。结果 7天后两组有效率分别为78%和67.39%。差异无统计学意义。在治疗14天两组有效率分别为94%和80.44%,差异有统计学意义。治疗组复发率为7.89%,对照组的复发率为39.29%。结论丁酸氢化可的松乳膏联合重组人表皮生长因子凝胶在婴幼儿湿疹治疗中疗效明显,复发率低且无不良反应。
Objective To observe the efficacy and safety of hydrocortisone butyrate cream combined with recombinant human epidermal growth factor gel in treatment of infantile eczema. Methods Divided the selected 96 patients of infantile eczema into two groups randomly, hydrocortisone butyrate creams were used combined with recombinant human epidermal growth factor gel twice per day alternatively, and was maintained after the rash cured later in the treatment group. Hydrocortisone butyrate creams were used only twice per day and the therapy was changed to once every day after the rash disappeared in the control group. The courses of treatment in both groups were 14 days. The variations of the rash were recorded in 7,14 days after medication and 7 days after recovery. Results At 7 days after therapy, the effective rates in the treatment group and the control group were respectively 78% and 67.39%. There were no significant difference between two groups（P〈0.05）. Which were 94% and 80.44% after 14 days of therapy. There were significant differences（P〈0.05）. The relapse rate in the treatment group was 7. 89% ,and in the control group was 39. 29%. Conclusion It is a very effective,low recurrence and safe method that hydrocortisone butyrate cream combined with recombinant human epidermal growth factor gel in treatment of infantile eczema.
出处
《中国冶金工业医学杂志》
2013年第5期511-512,共2页
Chinese Medical Journal of Metallurgical industry
